Hypertrophic Cardiomyopathy: Analyzing a Historical Series

75% of patients with hypertrophic Cardiomyopathy present symptoms. An important group responds very well to pharmacological treatment with betablockers and calcium antagonists, and those who do not respond, or do not tolerate these drugs, receive, at present, surgery as elective treatment. 

Miocardiopatía hipertrófica: análisis de una serie histórica

There is also alcohol septal ablation as an alternative strategy, which different studies have found favorable, even though its true benefit remains unclear, as well as the group of patients that would benefit from this treatment.  

The study looked at patients undergoing surgical septal myectomy and alcohol septal ablation (ASA) since 1998 to 2019 at the Mayo Clinic and the Fuwai Hospital. In all, it included 3274 patients undergoing septal myectomy and 585 ASA.

Primary end point was all cause mortality.

The ASA patients were older, had more hypertension, diabetes, kidney failure and heart disease, but had smaller septal thickness (19 mm vs 20 mm p=0.007) and no difference in gradient. 

At 30 days, mortality resulted similar: 0.7% vs 0.3% for ASA and septal myectomy respectively.

Read also: ACC 2022 | VALOR-HCM: Mavacamten in Adults with Symptomatic Obstructive HCM Eligible for Septal Reduction Therapy.

At 10 years, primary end point was higher in patients who had received ASA (26.1% vs. 8.2%), which was maintained after adjusting for variables such as age, sex and comorbidities (HR: 1.68; 95% CI: 1.29-2.19; P < 0.001).

Other parameters associated to mortality were functional class III-IV, obstructive pulmonary disease, stroke, atrial fibrillation, renal failures, diabetes and septal thickness, 

Conclusion

In patients with hypertrophic cardiomyopathy, alcohol septal ablation is associated with higher mortality in the long term, regardless other known factors, even though it might be affected by confounding factors overlooked as patient characteristics. 

Dr. Carlos Fava - Consejo Editorial SOLACI

Dr. Carlos Fava.
Member of the Editorial Board of SOLACI.org .

Original Title: Survival Following Alcohol Septal Ablation or Septal Myectomy for Patients With Obstructive. Hypertrophic Cardiomyopathy.

Reference: Hao Cui, et al. (J Am Coll Cardiol 2022;79:1647–1655).


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...

TCT 2024 | TRISCEND II: A New Hope in Percutaneous Tricuspid Valve Replacement

Advanced tricuspid regurgitation (TR) is a debilitating disease associated with heart failure and increased mortality.  Edge-to-edge repair has been shown to improve both clinical condition...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....